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Summary 
Background: High molecular weight (HMW) adiponectin
has antiatherogenic, antiinflammatory and antidiabetic
properties and these effects have been linked to its effect
on high density lipoprotein cholesterol (HDL-c). Single
nucleotide polymorphisms (SNPs) in the adiponectin gene
influence adiponectin levels. We examined the relationship
between HMW-adiponectin levels and cardiometabolic
traits in normo- and hyperglycemic mixed ancestry South
Africans and correlated these levels to two common poly-
morphisms.
Methods: HMW-adiponectin was determined in 101 sub-
jects from the Cape Town Bellville South community-based
study on a mixed ancestry population. Comparisons were
made between individuals with normo- and hyperglycemia.
Two common SNPs, ADIPOQ SNPs rs17300539 and
rs266729, known to affect adiponectin levels were also
tested for. Levels of HMW-adiponectin were then correlat-
ed with cardiometabolic traits in all groups.
Results: Levels of HMW-adiponectin were not significantly
different in the normo- and hyperglycemic groups (median
11.6 vs. 10.5 mg/mL, p=0.3060) and in men and women
(8.44 vs. 11.34 mg/mL, p=0.67). ADIPOQ SNPs
rs17300539 and rs266729 did not influence levels of
Kratak sadr`aj
Uvod: Adiponektin velike molekulske te`ine (VMT) ima anti-
aterogena, antiinflamatorna i antidijabetska svojstva i ovi
efekti su dovedeni u vezu s njegovim dejstvom na HDL holes-
terol (HDL-h). Polimorfizmi pojedina~nih nukleotida (SNP) u
genu za adiponektin uti~u na nivoe adiponektina. Ispitivali
smo odnos izme|u nivoa adiponektina VMT i kardiometa -
boli~kih odlika kod Ju`noafrikanaca me{ovite rase sa normo -
glikemijom i hiperglikemijom i napravili korelaciju izme|u
ovih nivoa i dva ~esta polimorfizma.  
Metode: Adiponektin VMT odre|en je kod 101 ispitanika
me{ovite rase iz zajednice Ju`ni Belvil u Kejptaunu koja je
kao populacija obuhva}ena studijom. Pore|enja su izvr{ena
izme|u pojedinaca sa normoglikemijom i hiperglikemijom.
Dva uobi~ajena SNP-a, polimorfizmi pojedina~nih nukleotida
ADIPOQ rs17300539 i rs266729, za koje se zna da uti~u
na nivoe adiponektina, tako|e su testirani. Nivoi adiponekti-
na VMT su zatim dovedeni u korelaciju sa kardiometa -
boli~kim odlikama u svim grupama. 
Rezultati: Nivoi adiponektina VMT nisu se zna~ajno razliko-
vali izme|u grupa sa normoglikemijom i hiperglikemijom
(medijana 11,6 vs. 10,5 mg/mL, p=0,3060) niti izme|u
mu{ka raca i `ena (8,44 vs. 11,34 mg/mL, p=0,67). Poli -
morfizmi pojedina~nih nukleotida ADIPOQ  rs17300539 i
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Introduction
Adiponectin is the most common adipokine
secreted by adipose tissue and increased visceral fat
accumulation inhibits its secretion (1–3). It plays an
important role in regulating glucose levels and fatty
acid oxidation by enhancing insulin sensitivity and
decreasing free fatty acid production (2, 4). It is
known to have antiatherogenic, antiinflammatory and
antidiabetic properties (5, 6). Higher circulating
adiponectin concentrations are associated with
reduced plasma glucose and serum triglyceride levels
and increased high density lipoprotein cholesterol
concentrations, decreased blood pressure and a
lower risk of obesity and type 2 diabetes (2, 4, 6–8).
It is thought that the lower adiponectin levels
observed in obesity and diabetes may be due to
inhibitory effects of inflammatory cytokines such as
tumour necrosis factor (TNF)-a, interleukin (IL)-6 and
IL-8. Additionally, adiponectin stimulates the produc-
tion of nitrous oxide and inhibits the expression of
adhesion molecules (2, 3, 5, 9). As such, adiponectin
levels were suggested as a therapeutic target for low-
ering the risk of developing metabolic syndrome, type
2 diabetes and cardiovascular disease (10). Sub se -
quently, several studies have described a paradox
where raised adiponectin levels are associated with
increased mortality especially in subjects with pre-
existing cardiovascular disease (11–18).
There are conflicting reports on the association
between body mass index (BMI), waist circumference,
insulin resistance, duration of diabetes and adipo -
nectin levels in Africans. The inconsistences may be
attributed to the different assays used to measure
adiponectin levels, renal status, molecular forms of
adiponectin and the influence of polymorphisms in
the adiponectin gene (19–22). It is now known that
adiponectin is secreted in low molecular weight
(trimer), medium molecular weight (hexamer) and
high molecular weight (HMW) (12–18mer) forms
(2–5, 23). The HMW form has been found to be the
active form and also has increased affinity to collagen
and is thus able to bind exposed collagen in damaged
vasculature, decrease apoptosis of endothelial cells
and increase reverse cholesterol transport due to its
effect on high density lipoprotein cholesterol (HDL-c)
(6, 8). Moreover, it is believed that between 30–70%
of the variability in adiponectin levels is influenced by
genetic factors (4, 8, 24). The adiponectin (ADIPOQ)
gene is located on chromosome 3q27, a susceptibili-
ty locus for metabolic syndrome and its components
(2, 6, 25). Numerous functional single nucleotide
polymorphisms (SNPs) and missense mutations have
been identified in various populations which may
affect adiponectin levels and impact on insulin sen -
sitivity and risk of cardiovascular disease (23). In
this regard, two adiponectin polymorphisms, rs
17300539 (11391 G>A) and rs266729 (11377
C>G) have been shown to be associated with risk for
type 2 diabetes by modulating adiponectin levels and
activity (23). Both these SNPs are in the promoter
region of the adiponectin gene and affect adiponectin
levels and thus the risk of metabolic syndrome, car-
diovascular disease and type 2 diabetes (26). In a
meta-analysis by Han et al. (27) rs266729 was asso-
ciated with lower adiponectin levels and type 2 dia-
betes risk in Whites, whereas rs17300539 was asso-
ciated with higher adiponectin levels and no
increased risk of type 2 diabetes unless there is a fam-
ily history of the disease. However, the association
between the adiponectin gene polymorphisms and
adiponectin levels varies across different populations
and some studies have found that rs17300539 is
indeed associated with increased risk of metabolic
syndrome and type 2 diabetes (26). Kaftan et al. (28)
described that both homozygous and heterozygous
mutations of rs 266729 are associated with an
increased risk of type 2 diabetes in Iraqis, but that
conflicting results have been found in other popula-
tions. These conflicting results of genetic studies may
be due to differences in age, genetic and ethnic back-
grounds of the study populations (26, 28).
Not much is known about the effect of BMI,
insulin resistance, glycemia and obesity on the HMW
form of adiponectin and how these are affected by
commonly reported polymorphisms in the adipo -
nectin gene in African populations. In this study, we
examined the relationship between HMW-adiponectin
HMW-adiponectin. Robust correlation analyses revealed a
significant positive correlation between HMW-adiponectin
and HDL-c (r=0.45; 95%CI: 0.27–0.59), similarly in
normo- and hyperglycemic participants (p>0.99). This
association was substantially attenuated in robust linear
regressions adjusted for age, gender and adiposity.
Conclusions: Adiponectin levels in this population were not
determined by the commonest SNPs of the adiponectin
gene, were unaffected by glycemic status; but were signif-
icantly correlated with HDL-c levels. Previous studies have
attributed some of the beneficial effects of adiponectin to
its effect on HDL-c.
Keywords: HMW-adiponectin, hyperglycemia, cardio -
metabolic traits, polymorphisms
rs266729 nisu uticali na nivoe adiponektina VMT. Robusne
korelacione analize pokazale su da postoji zna~ajna pozitivna
korelacija izme|u adiponektina VMT i HDL-h (r=0,45;
95%CI: 0,27–0,59) sli~na kod ispitanika sa normoglikemi-
jom i hiperglikemijom (p>0,99). Ova povezanost je znatno
oslabila nakon robusnih linearnih regresija prilago|enih
prema starosti, polu i adipozitetu. 
Zaklju~ak: Nivoi adiponektina u ovoj populaciji nisu bili
odre |eni naj~e{}im polimorfizmima pojedina~nih nukleotida
gena za adiponektin, niti je na njih uticao glikemijski status,
ali su bili u zna~ajnoj korelaciji sa nivoima HDL-h. Prethodne
studije su neke od povoljnih efekata adiponektina pripisale
njegovom dejstvu na HDL-h. 
Klju~ne re~i: adiponektin VMT, hiperglikemija, kardio -
metaboli~ke odlike, polimorfizmi  
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levels and cardiometabolic traits in normo-and hyper-
glycemic subjects of a mixed ancestry South African
population. We further investigated whether these
levels were influenced by two commonly reported
adiponectin polymorphisms, namely rs17300539
and rs266729.
Materials and Methods
Study setting and population
The study setting has been described in details
elsewhere (29–31). Briefly, participants were mem-
bers of a cohort study conducted in Bellville South,
Cape Town, a mixed ancestry township formed in the
late 1950s. Eligible participants were invited to take
part in a community based survey. All participants
were adults of mixed ancestry race.
Anthropometric measurements
All consenting participants received a standard-
ized interview and physical examination during which
blood pressure was measured according to WHO
guidelines (32) using a semiautomated digital blood
pressure monitor (Rossmax PA, USA). Other clinical
measurements included the body weight, waist and
hip circumferences. Participants underwent a stan-
dard two hour 75 g oral glucose tolerance test
(OGTT) as prescribed by the World Health Orga -
nization (WHO), with fasting and 2-hour plasma glu-
cose being determined. Impaired glucose tolerance
(IGT) and impaired fasting glucose (IFG) were diag-
nosed based on WHO criteria (33). Normoglycemia
was defined as normal fasting glucose levels and nor-
mal response to 75 g OGTT, whereas hyperglycemia
was defined as known diabetes, screen detected dia-
betes, IGT and/or IFG.
Laboratory measurements
Fasting whole blood and serum samples were
collected and processed for further analysis.
Separated serum was stored at –70  °C. Plasma glu-
cose was measured by enzymatic hexokinase method
(Cobas 6000, Roche Diagnostics). Glycated hemo-
globin (HbA1c) was assessed by turbidimetric in -
hibition immunoassay (Cobas 6000, Roche Diag -
nostics). This method is National Glyco hemoglobin
Standardization Programme (NGSP) certified accord-
ing to Roche Diagnostics. Total cholesterol, HDL-c
and triglycerides (TG) were estimated by enzymatic
colorimetric methods (Cobas 6000, Roche Diag -
nostics). Insulin was determined by a microparticle
enzyme immunoassay (Axsym, Abbott). C-reactive
protein (CRP) was measured by a high-sensitivity CRP
assay, based on the highly sensitive Near Infrared
Particle Immunoassay rate methodology (Immageâ
Immunochemistry System; Beckman Coulter). 
Levels of HMW-adiponectin were measured in
duplicate on serum by a sandwich ELISA (DRG®
Adiponectin Human (HMW) ELISA). The assay is spe-
cific for HMW-adiponectin and has no interference
from medium or low molecular weight adiponectin.
The limit of sensitivity of the assay is 0.5 mg/mL and
the appropriate range is 1.56–200 mg/mL. Serum
samples were stored and are stable at –70 °C.
Genotyping
Genomic DNA was extracted from whole blood
samples collected in an EDTA tube. Single nucleotide
polymorphisms, ADIPOQ rs266729 and ADIPOQ
rs17300539, were genotyped using high throughput
real-time polymerase chain reaction (RT-PCR) in two
independent laboratories on the ABI Prism 7900HT
platform (Applied Biosystems, USA) and a BioRad
Optica (BioRad, USA) using Taqman genotyping
assay (Applied Biosystems, USA). Direct sequencing
was used for analytical validation of high throughput
genotyping against direct sequencing as the gold
standard.
Definitions and calculations
The BMI was calculated as weight per square
meter (kg/m2) and waist-hip-ratio (WHR) as waist/hip
circumferences (cm). Diabetes was based on a histo-
ry of doctor-diagnosis, fasting blood glucose con -
centration ≥ 7.0 mmol/L and/or 2-hour post-OGTT
plasma glucose ≥ 11.1 mmol/L (33). The homeosta-
tic model assessment of insulin resistance (HOMA-IR)
was calculated according to the formula: HOMA-IR=
[fasting insulin concentration (mIU/L) × fasting plas-
ma glucose (mmol/L)/ 22.5] (34). Low density lipo -
protein cholesterol (LDL-c) was calculated using
Friedewald’s formula (35).
Ethics
The study was approved by the Cape Peninsula
University of Technology Faculty of Health and Well -
ness Sciences ethics committee (Reference Number:
CPUT/HW-REC 2008/002, CPUT/HW-REC 2010,
NHREC: REC–230 408–014 and N14/01/003) and
the University of Stellenbosch (N09/03/090). The
study was conducted according to the Code of Ethics
of the World Medical Association (Declaration of
Helsinki). All participants signed written informed
consent after all the procedures had been fully
explained in the language of their choice. 
Statistical methods
The statistical software programmes, STATISTI-
CA 12 (StatSoft, Inc) and R (version 3.0.3 [2014-03-
04], The R Foundation for statistical computing,
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Vienna, Austria) were used for statistical analyses.
The Shapiro-Wilk W test was used to determine the
distribution of HMW-adiponectin. Due to the skewed
distribution, nonparametric tests were used and the
median and lower and upper quartiles (25Q, 75Q)
were used for descriptive statistics of the general char-
acteristics of the study group. The Mann-Whitney U
test was used to compare subgroups. Robust correla-
tions were used to investigate the continuous associ-
ations between continuous variables and adiponectin
levels, and the potential effects of extraneous factors
adjusted for in robust linear regression models. SNPs
were tested for departure from Hardy-Weindberg
Equilibrium (HWE) expectation via a chi square good-
ness of fit test. Results corresponding to p-values
below 5% are described as significant. We did not
adjust for multiple testing. 
Results
A total of 101 mixed ancestry subjects with a
median age of 58 years were analysed: 38 had normo-
glycemia and 63 had hyperglycemia. The demo-
graphic data of our cohort is shown in Table I with
normoglycemia compared to hyperglycemia. Signifi -
cant differences between the two groups were found
for HOMA-IR, HbA1c, triglycerides, HDL-c, BMI and
WHR. Only 14 of the subjects were males and sepa-
rate analysis found no significant gender difference in
HMW-adiponectin levels (median 8.44 mg/mL in
males and 11.34 mg/mL in females; p=0.67) and
therefore we did not further stratify according to gen-
der. There was no significant difference in HMW-
adiponectin levels between the normoglycemic and
hyperglycemic groups (median 11.6 vs. 10.5 mg/mL;
p=0.306). 
ADIPOQ rs17300539 was in HWE (p=0.8535),
whilst ADIPOQ rs266729 was not (p=0.0201). The
HMW-adiponectin levels were higher in individuals with
heterogeneous ADIPOQ_2_17300539 AG when
compared to homozygous GG, respectively [median
(25th–75th percentile): 12.97 (9.22–20.12) and
11.57 (4.99–16.40); p=0.4547], however, only three
individuals carried the A allele. 
Table II shows correlation of HMW-adiponectin
with the variables for the group as a whole and sepa-
rately for the normo- and hyperglycemia groups.
Using Spearman Rank Order correlations, HMW-
adipo nectin was found to correlate significantly with
HDL-c and age and inversely with triglycerides, BMI
and WHR in the total group. In the normoglycemic
group, HMW-adiponectin correlated significantly with
HDL-c and inversely with HOMA-IR, triglycerides,
total cholesterol, BMI and WHR. In the hyperglycemic
group, the only significantly correlation was with
HDL-c. 
Using robust correlation statistics to eliminate
the effect of outliers and account for possible non-lin-
ear correlation, we found that HDL-c was significant-
ly correlated with HMW-adiponectin in overall,
normo glycemic and hyperglycemic groups. BMI cor-
related inversely in the normal group but not in hyper-
glycemia. Waist circumference had inverse significant
correlation in the overall sample likely driven by a
negative correlation in the normoglycemic group and
a non-significant correlation in the hyperglycemic
group. A similar pattern was observed with WHR. The
correlation with triglycerides and LDL-c was only in
the normoglycemic group, with evidence that the cor-
relation coefficients were significantly different across
glycemic status for LDL-c (p<0.001) (Table III).
In robust linear regressions adjusted for age,
gender and BMI, none of the covariates was signifi-
cantly associated with adiponectin levels. For HOMA-
IR, LDL-c and to lesser extent triglycerides, there was
suggestion of significant interaction with status for
glycemia, on their effects on adiponectin levels (Table
IV). 
Discussion
In this study, we investigated the relationship
between two common polymorphisms reported in the
adiponectin gene and HMW-adiponectin in mixed
ancestry South Africans, and further examined its re -
lationship with insulin resistance and cardiometabolic
traits in normo- and hyperglycemic subjects. Most
studies have established total adiponectin levels as a
marker of insulin resistance. However, this association
has not been observed consistently in African popula-
tions. This has been attributed to variability in adipo -
nectin’s secretion due to genetic differences. Ebinu ma
et al. developed a novel ELISA to determine HMW-
adiponectin levels in 2006 which was followed by the
development of ELISA assays to specifically determine
this fraction of adiponectin (36). A probable reason
for the limited studies on HMW-adipo nectin from
Africa is that until recently there was no reliable assay
and even when available, the cost is prohibitive.
We found no difference in HMW-adiponectin
levels between the normo- and hyperglycemic
groups, despite the higher degree of insulin resist-
ance in the latter group. Epidemiological studies
demonstrate an association between lower adipo -
nectin and the prevalence and incidence of insulin
resistance, and type 2 diabetes in various populations
(37). There are indications that this progression to
diabetes associated with low adiponectin levels is
modulated by insulin resistance (11,386). A recent
meta-analysis emphasized the substantial inverse
asso ciation between total plasma adiponectin levels
and the incidence of type 2 diabetes, which was clearly
consistent in various populations (37). 
A study from the United States found paradox-
ically high total adiponectin (PHA) levels in obese
metabolically healthy Afro-Americans and also
J Med Biochem 2016; 35 (4) 419
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Table I Demographic data of study cohort according to glycemic status.
HMW: high molecular weight, HOMA-IR: homeostatic model assessment of insulin resistance
Total (N 101) Normal (N 38) Hyperglycemia (N 63)
Median 
(25th–75th percentiles)
Median 
(25th–75th percentiles)
Median 
(25th–75th percentiles) P-value
HMW-adiponectin
(mg/mL) 11.1 (6.3–16.4) 11.6 (6.3–16.8) 10.5 (5.2–16.4) 0.31
Age (years) 58 (50–64) 59 (47–64) 57 (52–64) 0.77
Fasting blood glucose
(mmol/L) 5.9 (5.0–8.0) 5.1 (4.7–5.3) 7.4 (6.0–10.0) < 0.0001
2-hour glucose (mmol/L) 7.6 (5.7–9.0) 5.7 (5.4–6.2) 8.9 (8.1–14.9) < 0.0001
Fasting insulin (mU/L) 11.4 (6.1–17.0) 36.7 (27.8–61.4) 57.3 (24.9–129.3) 0.06
HOMA-IR 3.5 (1.6–5.2) 2.3 (1.2–3.4) 3.9 (1.8–7.0) 0.0021
HbA1c (%) 6.1 (5.7–6.8) 5.7 (5.6–6.0) 6.3 (6.1–8.1) < 0.0001
C-reactive protein (mg/L) 5.4 (1.9–10.4) 4.2 (1.2–10.7) 5.9 (2.3–10.4) 0.28
Triglycerides (mmol/L) 1.4 (1.1–1.9) 1.1 (0.8–1.5) 1.7 (1.3–2.1) < 0.0001
HDL-cholesterol (mmol/L) 1.2 (1.1–1.5) 1.4 (1.2–1.7) 1.1 (1.0–1.4) 0.0006
LDL-cholesterol (mmol/L) 3.8 (3.1–4.5) 3.7 (3.2–4.4) 3.9 (3.1–4.5) 0.55
Total cholesterol (mmol/L) 5.8 (5.1–6.6) 5.8 (5.0–6.5) 5.9 (5.2–6.7) 0.52
Height (m) 1.6(1.5–1.6) 1.6 (1.5–1.6) 1.6 (1.5–1.6) 0.02
Weight (kg) 80.3 (72.4–88.0) 71.5 (59.1–85.0) 81.5 (75.0–89.5) 0.01
Body mass index (kg/m2) 32.3 (28.2–36.5) 30.6 (24.6–34.6) 32.6 (29.1–38.4) 0.04
Waist circumference (cm)  100.0 (93.5–108.0) 93.6 (84.0–102.3) 102.0 (96.5–112.3) 0.0007
Hip circumference (cm) 113.0 (104.0–120.0) 107.7 (99.0–117.5) 115.0 (105.0–121.0) 0.06
Waist-to-hip ratio 0.88 (0.84–0.93) 0.87 (0.81–0.90) 0.89 (0.85–0.96) 0.01
Systolic blood pressure
(mmHg) 130 (119–140) 126 (115–135) 132 (123–142) 0.15
Diastolic blood pressure
(mmHg) 80 (71–86) 81 (75–87) 79 (69–86) 0.31
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reported gender differences despite having higher
BMIs and waist circumferences (39). We did not
observe gender differences despite a higher degree
of obesity in females and speculate PHA as a possi-
ble cause, though numerous other studies have
described higher adiponectin levels in females (2,
25, 40). However, Moriyama et al. (41) also found
no gender difference in their study. Another possible
factor that may have contributed in our study may be
the extremely low number of males in our cohort
(only 14 out of 101). 
Recent studies have also described the so-called
»adiponectin paradox« where raised adiponectin
levels are associated with increased mortality, espe-
cially in older individuals with pre-existing cardiovas-
cular disease (11–18). The reason for this is still un -
known, but adiponectin resistance at receptor level,
increased adiponectin levels in response to raised N-
terminal fragment of pro-brain natriuretic peptide
(NT-proBNP), and an increase in proinflammatory
cytokines have been postulated (12, 16–18, 42).
It is difficult to compare our results with these
studies, as to our knowledge only two studies have
reported HMW-adiponectin in South African popula-
tions. In one, levels of HMW- and total adiponectin
were determined in HIV-infected women both on and
off antiretroviral therapy and it was determined that
levels of HMW-adiponectin were lower in the treat-
J Med Biochem 2016; 35 (4) 421
Table II Correlation between HMW-adiponectin and parameters tested.
Total
N101
Normal
N38 Hyperglycemia
R P-value R P-value R P-value
Age (years) 0.1991 0.05 0.2743 0.10 0.1439 0.26
Fasting blood glucose
(mmol/L) -0.0452 0.65 0.1134 0.50 -0.0591 0.65
2-hour glucose (mmol/L) 0.0492 0.67 -0.0174 0.92 0.1894 0.24
Fasting insulin (mU/L) -0.1581 0.12 -0.4148 0.01 0.0028 0.98
HOMA-IR -0.1510 0.13 -0.4212 0.01 -0.0768 0.55
% HbA1c -0.1456 0.15 -0.0906 0.59 -0.1332 0.30
C-reactive protein (mg/L) -0.0913 0.36 -0.1845 0.27 0.0113 0.93
Triglycerides (mmol/L) -0.2616 0.01 -0.5130 <0.05 -0.1208 0.35
HDL-cholesterol (mmol/L) 0.3361 <0.05 0.3525 0.03 0.2758 0.03
LDL-cholesterol (mmol/L) 0.1075 0.29 0.2951 0.08 0.0080 0.95
Cholesterol (mmol/L) 0.1802 0.07 0.3810 0.02 0.0777 0.55
Height (m) -0.0730 0.47 0.2855 0.09 -0.2026 0.11
Weight (kg) -0.1812 0.15 -0.4379 0.06 -0.0655 0.67
Body mass index (kg/m2) -0.2262 0.02 -0.4072 0.01 -0.0677 0.60
Waist circumference (cm)  -0.2267 0.02 -0.4398 0.01 -0.0904 0.48
Hip circumference (cm) -0.0992 0.32 -0.3527 0.03 0.0764 0.55
Waist-to-hip ratio -0.2279 0.02 -0.3397 0.04 -0.1607 0.21
Systolic blood pressure
(mmHg) -0.0496 0.62 0.0439 0.80 -0.0347 0.79
Diastolic blood pressure
(mmHg) -0.0640 0.53 0.0626 0.71 -0.1597 0.21
HOMA-IR: homeostatic model assessment of insulin resistance
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ment group and inversely correlated with waist cir-
cumferences, insulin and HOMA-IR (43). Another
study examined levels of HMW- and total adiponectin
and other markers of endothelial dysfunction in Black
and White South Africans with rheumatoid arthritis.
They found no ethnic differences and significant
associations with glucose and lipid profile (44). Whilst
Meilleur et al. (45) and Sobngwi et al. (21) showed a
significant association between total adiponectin lev-
els and either insulin resistance or obesity in West
Afri cans, Ferris et al. (20) from South Africa and
Orluwene and Kasia (46) from Nigeria did not
observe this relationship. Similarly, Ntyintyane et al.
(47) from South Africa also observed no relationship.
In contrast to observations made in this study, numer-
ous Japanese studies have reported an association
between HMW-adiponectin and insulin resistance
(41, 48–52) and found it to be a better predictor of
insulin resistance, type 2 diabetes progression, meta-
bolic syndrome and coronary artery disease predic-
tion in patients with type 2 diabetes (48–50). As our
study was cross-sectional, it is difficult to evaluate the
prognostic value of our findings.
As variability in adiponectin levels in different
ethnic groups has also been attributed to polymor-
phisms in the adiponectin gene, we investigated the
role of two commonly reported polymorphisms and
found that these did not affect HMW-adiponectin lev-
els nor did they have an association with insulin resist-
ance or components of the metabolic syndrome.
Karmelic et al. studied the same polymorphisms as in
this study and found that there was a significant
decrease in total adiponectin with metabolic syn-
drome traits and that levels correlated with central
obesity and triglyceride levels (24). A study by Lin et
al. (53) described ethnic differences in the incidence
of polymorphisms and found that rs266729 de -
creased adiponectin levels and increased the risk of
metabolic syndrome in Chinese. Similarly Vasseur et
al. (23) also described an increased incidence of type
2 diabetes with the rs266729 polymorphism and an
association between rs266729 and coronary artery
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Table III Robust Correlation of HMW-adiponectin (mg/mL) with biochemical and anthropometric parameters.
HOMA-IR: homeostatic model assessment of insulin resistance
Correlates Overall N=96 Normal N=36 Hyperglycemia N=60 P
Age (years) 0.20 (0.00 to 0.38) 0.22 (-12 to 0.51) 0.15 (-0.11 to 0.39) 0.76
Fasting blood glucose
(mmol/L) 0.01 (-0.19 to 0.21) 0.05 (-0.28 to 0.38) -0.01 (-0.26 to 0.25) 0.78
Fasting insulin (mU/L) -0.12 (-0.32 to 0.08) -0.39 (-0.64 to 0.07) 0.06 (-0.20 to 0.31) 0.03
HOMA-IR -0.09 (-0.28 to 0.12) -0.35 (-0.61 to -0.03) 0.02 (-0.23 to 0.28) 0.07
% HbA1c -0.08 (-0.28 to 0.12) -0.14 (-0.44 to 0.20) -0.09 (-0.34 to 0.16) 0.84
Triglycerides (mmol/L) -0.21 (-0.14 to 0.07) -0.46 (-0.68 to -0.15) -0.07 (-0.32 to 0.19) 0.05
HDL-cholesterol (mmol/L) 0.45 (0.27 to 0.59) 0.42 (0.11 to 0.66) 0.42 (0.19 to 0.61) >0.99
LDL-cholesterol (mmol/L) 0.19 (-0.01 to 0.37) 0.53 (0.24 to 0.73) 0.05 (-0.30 to 0.20) <0.001
Body mass index (kg/m2) -0.17 (-0.36 to 0.03) -0.33 (-0.59 to 0.00) 0.005 (-0.25 to 0.26) 0.11
Waist circumference (cm)  -0.23 (-0.41 to -0.03) -0.39 (-0.64 to 0.07) -0.04 (-0.29 to 0.22) 0.09
Hip circumference (cm) -0.10 (-0.30 to 0.10) -0.22 (-0.51 to 0.11) 0.04 (-0.22 to 0.29) 0.23
Waist-to-hip ratio -0.21 (-0.40 to -0.01) -0.39 (-0.64 to 0.07) -0.08 (-0.33 to 0.17) 0.13
Systolic blood pressure
(mmHg) 0.03 (-0.17 to 0.23) 0.16 (-0.17 to 0.47) -0.03 (-0.28 to 0.22) 0.37
Diastolic blood pressure
(mmHg) 0.01 (-0.19 to 0.21) 0.20 (-0.14 to 0.50) 0.11 (-0.35 to 0.15) 0.15
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disease was reported by Fisman and Teenbaum (10).
Furthermore, in a meta-analysis Han et al. (27) con-
cluded that rs17300539 was not associated with an
increased risk of type 2 diabetes, but that rs266729
decreased total adiponectin levels and increased the
risk of diabetes. In the Erasmus Rucphen study in
Netherlands, rs17300539 was found to be associat-
ed with plasma insulin levels and HOMA-IR due to
functional variation of the adiponectin protein which
affected insulin sensitivity independently of adipo -
nectin levels (54). Kaftan et al. (28) found that
rs266729 was associated with type 2 diabetes and
also had an effect on HDL-c in an Iraqi population;
however, they did not perform serum adiponectin lev-
els. In contrast to these observations, Gao et al. (55)
found no association between rs266729 polymor-
phism and metabolic syndrome in a Chinese popula-
tion which they felt was due to their small study pop-
ulation and additionally they did not correlate their
results with serum adiponectin levels. 
Several studies have postulated that the most
important beneficial effect of adiponectin may be due
to its effect on HDL-c and the reverse cholesterol
transport (8). A sub-study of The Nurses’ Health
Study in United States found that HMW-adiponectin
was protective and that this effect was mainly due to
increased HDL-c, with these effects being stronger in
younger women (56). While another study on the
same Nurses’ Health Study found that HMW-adipo -
nectin was associated with an increased risk in wo -
men who developed type 2 diabetes (57), the British
Women’s Heart and Health study found no associa-
tion between HMW-adiponectin and coronary heart
Table IV Robust linear regressions (age, gender, BMI adjusted) showing the effects of covariates on HMW-adiponectin levels.
HOMA-IR: homeostatic model assessment of insulin resistance
Variables Overall N=96 P interaction with glycemic status
 (se) p-value
Age (years) 0.070 (0.098) 0.473 0.760
Sex (women) 2.031 (3.413) 0.553 0.424
Fasting blood glucose
(mmol/L) -0.179 (0.327) 0.586 0.658
Fasting insulin (mU/L) -0.004 (0.087) 0.961 0.156
HOMA-IR -0.060 (0.309) 0.845 0.032
% HbA1c -0.588 (0.391) 0.136 0.435
Triglyceride (mmol/L) -1.243 (1.330) 0.353 0.086
HDL-cholesterol (mmol/L) 5.836 (3.520) 0.101 0.966
LDL-cholesterol (mmol/L) 0.654 (1.191) 0.584 0.058
Body mass index (kg/m2) -0.225 (0.167) 0.182 0.515
Waist circumference (cm)  -0.058 (0.126) 0.648 0.109
Hip circumference (cm) 0.041 (0.075) 0.584 0.357
Waist-to-hip ratio -15.861 (10.867) 0.148 0.187
Systolic blood pressure
(mmHg) -0.001 (0.050) 0.982 0.953
Diastolic blood pressure
(mmHg) 0.014 (0.090) 0.877 0.839
Normoglycemia 1.158 (1.689) 0.495 -
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disease, although levels were inversely associated
with WHR, fasting insulin, glucose, HOMA-IR, triglyc-
erides and HDL-c (58). Moriyama et al. (41) deter-
mined that HMW-adiponectin was associated with the
metabolic syndrome mainly due to its effect on HDL-
c by influencing its size. In a South African study on
total adiponectin levels, Ferris et al. (20) found that
although total adiponectin did not correlate with
insulin resistance after correcting for BMI and ethnic-
ity, levels did have a role in determining HDL-c levels.
A previous study where adipocytes were incubated
with HDL-c found that the HDL upregulated
adiponectin expression (59). As both HDL and adipo -
nectin activate AMP-kinase and decrease insulin lev-
els, adiponectin may mediate the insulin sensitizing
effects of HDL-c (60). 
There are numerous limitations that require con-
sideration. We had a small sample size with very few
male participants so could not divide our adipo nectin
levels into quartiles or reliably determine gender differ-
ences. Because of the high prevalence of obesity in
this population group the controls as well as subjects
with hyperglycemia were obese which may have
adversely affected the HMW-adiponectin levels in nor-
moglycemic subjects. Our population was older and
according to Pischon, adiponectin level is a better pre-
dictor in younger subjects. In contrast to findings by
Pischon (56), a meta-analysis by Wu et al. (14) found
that increased adiponectin levels may in fact be asso-
ciated with increased mortality in older subjects. The
cross-sectional nature of our study is a further limita-
tion. Despite these limitations, a unique and major
contribution to previous studies from Africa was the
measurement of HMW-adiponectin, known to be the
metabolically active form of adiponectin. Additio nally,
we used robust correlation and robust regressions
which avoid the effect of outliers and the issues with
the distribution of HMW-adiponectin and correlates. 
Conclusion
In our cohort of 101 adult South Africans, we
found no significant difference in HMW-adiponectin
levels between normo- and hyperglycemic subjects.
Furthermore, levels of adiponectin were not deter-
mined by common adiponectin polymorphisms
known to influence adiponectin levels. We did find
some correlations between HMW-adiponectin and
traits of the metabolic syndrome. However, the only
correlation that remained statistically significant in the
group as a whole and in both groups was with HDL-
c. This is in keeping with literature which describes
that one of the most important reasons for
adiponectin’s beneficial effect may be due to its effect
on HDL-c function and size and the reverse choles-
terol transport system. Further follow-up studies are
needed on a larger population with a more equal
gender distribution with lower BMI.
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